• Work with us
  • External Contractors
Fondazione Toscana Life Sciences
  • IT
  • EN
Toscana Life Sciences
  • THE FOUNDATION
    • Organization
    • History
    • Membership
    • The Legislative Decree No. 231/2001
    • Results
  • Activity
  • Cluster
  • ITS VITA
  • BIOINCUBATOR
    • Join the Bioincubator
    • Incubated companies
    • Research groups
    • Affiliated companies
  • Services
    • Business development services
    • Research services
    • Incubation services
    • Protection of intellectual property
  • Projects
    • Monoclonal Antibody Discovery (MAD) LAB
    • ERC Advanced Grant VACCIBIOME
    • TUMOUR IMMUNOLOGY UNIT
    • Mass Spectrometry Unit
    • BOTANICALS LAB
    • Data Science for Health (DaScH) Lab
    • Regions4PerMed
    • IDF SHARID
    • BORNTOGEtTHERe
    • SINO-EU‐PERMED
    • Orphan diseases
  • Disseminating
    • TLS Open Doors
    • Scientists for a day
    • Science + Economy = Business
    • Researcher’s Night
    • European Biotech Week
  • Stories
Enter any keyword and press enter

TUMOUR IMMUNOLOGY UNIT

  • Projects
    • Monoclonal Antibody Discovery (MAD) LAB
    • ERC Advanced Grant VACCIBIOME
    • TUMOUR IMMUNOLOGY UNIT
    • Mass Spectrometry Unit
    • BOTANICALS LAB
    • Data Science for Health (DaScH) Lab
    • Regions4PerMed
    • MammoScreen
    • IDF SHARID
    • BORNTOGEtTHERe
    • SINO-EU‐PERMED

TUMOUR IMMUNOLOGY UNIT

TUMour Immunology (TUMI) unit led by Dr. Anna Kabanova was established with a support of the Italian Association for Cancer Research program called "My First AIRC grant". My First AIRC aims to support young researchers in establishing independent laboratories to pursue cancer-related research.


TUMI team aims at getting deeper understanding of the mechanisms ensuring that some tumours are slower in the development than others and to harness this knowledge for therapy development. Specifically, we are interested in studying one of the most frequent tumours of B lymphocytes, the B-cell chronic lymphocytic leukemia (CLL), which is characterized by high incidence of indolent cases, suggesting that a molecular network suppressing tumour progression might be in place in CLL. Our knowledge on this network and its regulation is relatively fragmentary, therefore we aim to deepen it and use it to treat aggressive B cell tumours.


Molecular factors regulating B cell fitness and its relevance for CLL pathogenesis
CLL cells are endowed with a number of peculiar characteristics, including the expression of particular inhibitory immune receptors, such as ILT3, and various intracellular signaling proteins, which undergo dynamic redistribution upon CLL cell stimulation. We combine the state-of-the-art imaging, molecular and signaling studies to characterize functional significance of this process. Also, by a combination of proteomics, transcriptomics and gene editing approaches in vitro and in vivo, we study CLL-specific gene networks which inhibit B cell tumour development. Results of this study may allow us to understand better the biology of this disease and also may form a rationale for the development of novel therapeutic approaches to treat aggressive CLL, since about 30-40% of treated CLL tend to relapse. This expectation might be extended to other B cell lymphoproliferative disorders, because of the common cellular source of the tumour.


mRNA therapy to treat B cell tumours and to mimic B cell-promoted immunity
TUMI team is particularly interested in applying mRNA technologies as immunotherapeutics to treat CLL. To cultivate inner expertise and learn more about this cutting-edge versatile technology, we are currently collaborating with the Monoclonal Discovery lab lead in TLS by Dr. Rino Rappuoli and coordinated by Dr. Claudia Sala. TUMI is helping MAD lab to set up experimental pipelines for efficient and fast characterization of hundreds of anti-bacterial mAbs, formulated as mRNA, that are being developed to counteract the uprising threat of antimicrobial resistance (AMR). The project is supported by Wellcome Leap R3 consortium.

Contacts:

Cristina Tinti
c.tinti@toscanalifesciences.org


Principal Investigator of the Tumour Immunology Unit:

Anna Kabanova
a.kabanova@toscanalifesciences.org

Research Group:
Rosita del Prete
Roberta Drago
Federica Nardi
Alua Kabdolova
Mattia Apollonio

Fondazione Toscana Life Sciences
Via Fiorentina, 1
53100 Siena – ITALIA

  • tel +39 0577 231211
  • fax +39 0577 43444
  • info@toscanalifesciences.org

Twitter Feeds

🗣Se hai esperienza nel Project Management e sei alla ricerca di una nuova sfida professionale unisciti al Project M…

@FondazioneTLS About a Day Ago

🗣Studia, cresci, vola a Siena. Torna la terza edizione di STAYHub, un programma ideato dal polo SAIHUB con Fondazio…

@FondazioneTLS 4 Days Ago

🗣Le nostre imprese ⚙️fanno un'impresa eccezionale. Guardando alle aziende e ai gruppi di ricerca del bioincubatore…

@FondazioneTLS 6 Days Ago

Contatti

    Concedo il consenso al trattamento dei dati personali secondo la nostra Privacy Policy per poter essere contattato da Fondazione Toscana Life Sciences.

©2015-2021 - Fondazione Toscana Life Sciences - P.I. 01194710529 - Codice SDI: SUBM70N - Privacy - Cookie Policy